MedPath

Gruppo Italiano Malattie EMatologiche dell'Adulto

🇮🇹Italy
Ownership
Private
Employees
-
Market Cap
-
Website

Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

First Posted Date
2010-06-30
Last Posted Date
2022-10-26
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
11
Registration Number
NCT01154439
Locations
🇮🇹

Università La Sapienza, Roma, Italy

🇮🇹

Azienda Ospedaliera Universitaria - Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia, Napoli, Italy

🇮🇹

Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy

and more 2 locations

"AIDA" Protocol (LAP 0493)

Not Applicable
Conditions
Leukemia
First Posted Date
2010-02-08
Last Posted Date
2020-10-14
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
1068
Registration Number
NCT01064557
Locations
🇮🇹

U.O.C. Ematologia e Terapia Cellulare - Ospedale "C. e G. Mazzoni" di Ascoli Piceno, Ascoli, Italy

🇮🇹

S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

🇮🇹

Azienda Ospedaliera - Nuovo Ospedale "Torrette", Ancona, Italy

and more 77 locations

AIDA 2000 Guidelines

Phase 2
Conditions
Acute Promyelocytic Leukemia
First Posted Date
2010-02-08
Last Posted Date
2020-10-14
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
600
Registration Number
NCT01064570
Locations
🇮🇹

A.O Umberto I, Roma, Italy

🇮🇹

Unità Operativa Ematologia 1 - Università degli Studi di Bari, Bari, Italy

🇮🇹

Div. di Ematologia IRCCS Policlinico S. Matteo, Pavia, Italy

Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study

Phase 2
Completed
Conditions
Treatment
Stem Cell Transplantation
First Posted Date
2009-12-03
Last Posted Date
2022-10-12
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
40
Registration Number
NCT01025505
Locations
🇮🇹

Osp. Reg. A. Di Summa, Brindisi, Italy

🇮🇹

Clinica Ematologica - Università degli Studi, Genova, Italy

🇮🇹

U.O. Ematologia, Azienda Ospedaliera Universitaria Senese, Siena, Italy

and more 32 locations

Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy

Completed
Conditions
Chronic Myeloid Leukemia
Interventions
Other: HRQOL Survey Packet
First Posted Date
2009-05-11
Last Posted Date
2014-01-22
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
448
Registration Number
NCT00896129
Locations
🇮🇹

Università di Pisa, Azienda Ospedaliera Pisana, Pisa, Italy

🇮🇹

Policlinico G.B. Rossi, Verona, Italy

🇮🇹

Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy

and more 22 locations

Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes

Conditions
Adult
Myelodysplastic Syndromes
First Posted Date
2008-12-17
Last Posted Date
2020-12-22
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
927
Registration Number
NCT00809575
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York, United States

🇺🇸

The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

🇦🇹

Innsbruck University Hospital, Innsbruck, Austria

and more 50 locations

Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2008-10-20
Last Posted Date
2017-11-09
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
60
Registration Number
NCT00775593
Locations
🇮🇹

Policlinico G. B. Rossi - Borgo Roma, Verona, Italy

🇮🇹

Ospedale S. Eugenio, Roma, Italy

🇮🇹

S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena, Roma, Italy

and more 16 locations

Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2008-10-09
Last Posted Date
2022-01-04
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
129
Registration Number
NCT00769327
Locations
🇮🇹

Centro Oncologico Basilicata, Rionero in Vulture, Potenza, Italy

🇮🇹

Unità di Oncoematologia Azienda Ospedaliera Garibaldi, Catania, Italy

🇮🇹

Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga, Orbassano, Italy

and more 34 locations

Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy

Phase 1
Completed
Conditions
Chronic Lymphocytic Leukemia
First Posted Date
2008-08-04
Last Posted Date
2019-01-22
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
42
Registration Number
NCT00727415
Locations
🇮🇹

Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST, Meldola, Italy

🇮🇹

Unità Operativa Ematologia 1 - Università degli Studi di Bari, Bari, Italy

🇮🇹

Istituto di Ematologia e Oncologia Medica "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi, Bologna, Italy

and more 20 locations

Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura

Phase 3
Completed
Conditions
Nonneoplastic Condition
Interventions
Procedure: quality-of-life assessment
First Posted Date
2008-04-14
Last Posted Date
2017-02-20
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
150
Registration Number
NCT00657410
Locations
🇮🇹

S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

🇮🇹

USL 8 - Ospedale S.Donato, Arezzo, Italy

🇮🇹

UO Ematologia con trapianto- AOU Policlinico Consorziale di Bari, Bari, Italy

and more 39 locations
© Copyright 2025. All Rights Reserved by MedPath